EN
SINOVAC actively discusses COVID-19 Vaccine application and the industry development with other countries
The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong Yin, and Sales General Manager Helen Yang of Sinovac Group, and Deputy General Manager Weining Meng of Sinovac Life Sciences.
During the visit, H.E. Ambassador and Mr. Yin had a teleconference with the Minister of Health and Population of Egypt Prof. Hala Zayed on the supply and localization of SINOVAC's COVID-19 Vaccine, the procurement of other vaccine products, and also the cooperation of technology license. The two parties initially reached a cooperative intention on the above discussion.
On October 21, 2021, Sales General Manager Helen Yang of Sinovac Group welcomed The Philippines delegation led by Jose Santiago L. Sta. Romana, the Philippine Ambassador to China, and together with Venince Allen Carillo, the Third Secretary, and Data Dada, the Attache.
H.E. Ambassador Romana signed the delivery certification of the second batch of CHINA AID 1 million COVID-19 vaccines to the Philippines and went to the cold storage to personally turn on the temperature recorder.
Embassy of the Republic of Indonesia in Beijing invited Sales General Manager Helen Yang of Sinovac Group to join the Indonesia-China Business Forum 2021 on the theme "New Road to Business Acceleration in Digitalization, Health and Green Economy in Indonesia" on Tuesday, 19 October 2021.
The event is organized with the Directorate General of Asia Pacific and Africa, Ministry for Foreign Affairs of the Republic of Indonesia, Bank Indonesia Representative Office in Beijing, and Indonesia Chamber of Commerce in China.
Ambassador of the Republic of Indonesia to the People's Republic of China, H.E. Mr. Djauhari Oratmangun, Vice-Minister for Foreign Affairs of the Republic of Indonesia, H.E. Mr. Mahendra Siregar attendance the forum and introduced the bilateral solid relationship development between Indonesia-China and achievements made so far and future focus on health, digitalization and green economy, etc. Industries cooperation between China and Indonesia.
Helen Yang introduced Indonesia as the first country to issue EUA Certificate to China, and further Indonesia and Sinovac close cooperation on clinical, vaccine supplies to make Indonesia be the largest COVID-19 vaccines manufacturer in ASEAN (Association of Southeast Asian Nations) countries, and also illustrates the confidence in plan to help Indonesia to be the vaccines manufacture hub.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.